Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'ORAL ALENDRONATE' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 91 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Dursun, N; Dursun, E; Yalcin, S
      Comparison of alendronate, calcitonin and calcium treatments in postmenopausal osteoporosis

      INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
    2. Aoyagi, K; Shiraki, M; Ito, M; Nakamura, T
      Statistical analysis for comparing antifracture efficacy among antiresorptive agents - Alendronate versus alfacalcidol and calcitonin

      CLINICAL DRUG INVESTIGATION
    3. Coyle, D; Cranney, A; Lee, KM; Welch, V; Tugwell, P
      Cost effectiveness of nasal calcitonin in postmenopausal women - Use of Cochrane collaboration methods for meta-analysis within economic evaluation

      PHARMACOECONOMICS
    4. Watts, NB; Jenkins, DK; Visor, JM; Casal, DC; Geusens, P
      Comparison of bone and total alkaline phosphatase and bone mineral densityin postmenopausal osteoporotic women treated with alendronate

      OSTEOPOROSIS INTERNATIONAL
    5. Watts, NB
      Treatment of osteoporosis with bisphosphonates

      RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
    6. Murphy, MG; Weiss, S; McClung, M; Schnitzer, T; Cerchio, K; Connor, J; Krupa, D; Gertz, BJ
      Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women

      JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM
    7. Sharpe, M; Noble, S; Spencer, CM
      Alendronate - An update of its use in osteoporosis

      DRUGS
    8. Lau, EMC; Woo, J; Chan, YH; Griffith, J
      Alendronate prevents bone loss in Chinese women with osteoporosis

      BONE
    9. Yen, ML; Yen, BL; Jang, MH; Hsu, SHJ; Cheng, WC; Tsai, KS
      Effects of alendronate on osteopenic postmenopausal Chinese women

      BONE
    10. Boivin, GY; Chavassieux, PM; Santora, AC; Yates, J; Meunier, PJ
      Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women

      BONE
    11. Rossini, M; Gatti, D; Girardello, S; Braga, V; James, G; Adami, S
      Effects of two intermittent alendronate regimens in the prevention or treatment of postmenopausal osteoporosis

      BONE
    12. Looker, AC; Bauer, DC; Chesnut, CH; Gundberg, CM; Hochberg, MC; Klee, G; Kleerekoper, M; Watts, NB; Bell, NH
      Clinical use of biochemical markers of bone remodeling: Current status andfuture directions

      OSTEOPOROSIS INTERNATIONAL
    13. Chavassieux, PM; Arlot, ME; Roux, JP; Portero, N; Daifotis, A; Yates, AJ; Hamdy, NAT; Malice, MP; Freedholm, D; Meunier, PJ
      Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: A histomorphometric analysis of transiliac biopsies

      JOURNAL OF BONE AND MINERAL RESEARCH
    14. Schnitzer, T; Bone, HG; Crepaldi, G; Adami, S; McClung, M; Kiel, D; Felsenberg, D; Recker, RR; Tonino, RP; Roux, C; Pinchera, A; Foldes, AJ; Greenspan, SL; Levine, MA; Emkey, R; Santora, AC; Kaur, A; Thompson, DE; Yates, J; Orloff, JJ
      Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis

      AGING-CLINICAL AND EXPERIMENTAL RESEARCH
    15. Tiras, MB; Noyan, V; Yildiz, A; Yildirim, M; Daya, S
      Effects of alendronate and hormone replacement therapy, alone or in combination, on bone mass in postmenopausal women with osteoporosis: a prospective, randomized study

      HUMAN REPRODUCTION
    16. Kung, AWC; Yeung, SSC; Chu, LW
      The efficacy and tolerability of alendronate in postmenopausal osteoporotic Chinese women: A randomized placebo-controlled study

      CALCIFIED TISSUE INTERNATIONAL
    17. Ezra, A; Golomb, G
      Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption

      ADVANCED DRUG DELIVERY REVIEWS
    18. Mincey, BA; Moraghan, TJ; Perez, EA
      Prevention and treatment of osteoporosis in women with breast cancer

      MAYO CLINIC PROCEEDINGS
    19. Downs, RW; Bell, NH; Ettinger, MP; Walsh, BW; Favus, MJ; Mako, B; Wang, LX; Smith, ME; Gormley, GJ; Melton, ME
      Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women

      JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM
    20. Fogelman, I; Ribot, C; Smith, R; Ethgen, D; Sod, E; Reginster, JY
      Risedronate reverses bone loss in postmenopausal women with low bone mass:Results from a multinational, double-blind, placebo-controlled trial

      JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM
    21. Ravn, P; Weiss, SR; Rodriguez-Portales, JA; McClung, MR; Wasnich, RD; Gilchrist, NL; Sambrook, P; Fogelman, I; Krupa, D; Yates, AJ; Daifotis, A; Fuleihan, GE
      Alendronate in early postmenopausal women: Effects on bone mass during long-term treatment and after withdrawal

      JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM
    22. Haderslev, KV; Tjellesen, L; Sorensen, HA; Staun, M
      Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease

      GASTROENTEROLOGY
    23. Bauer, DC; Black, D; Ensrud, K; Thompson, D; Hochberg, M; Nevitt, M; Musliner, T; Freedholm, D
      Upper gastrointestinal tract safety profile of alendronate - The Fracture Intervention Trial

      ARCHIVES OF INTERNAL MEDICINE
    24. Chapurlat, R; Delmas, PD
      Therapeutic strategies for osteoporosis.

      ANNALES DE MEDECINE INTERNE
    25. Greenspan, SL; Harris, ST; Bone, H; Miller, PD; Orwoll, ES; Watts, NB; Rosen, CJ
      Bisphosphonates: Safety and efficacy in the treatment and prevention of osteoporosis

      AMERICAN FAMILY PHYSICIAN
    26. Ravn, P; Clemmesen, B; Christiansen, C
      Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women

      BONE
    27. Rossini, M; Braga, V; Gatti, D; Gerardi, D; Zamberlan, N; Adami, S
      Intramuscular clodronate therapy in postmenopausal osteoporosis

      BONE
    28. Watts, NB; Becker, P
      Alendronate increases spine and hip bone mineral density in women with postmenopausal osteoporosis who failed to respond to intermittent cyclical etidronate

      BONE
    29. Hosking, DJ; Favus, M; Yates, AJ
      Alendronate in the treatment of postmenopausal osteoporosis

      INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
    30. Watts, N; Freedholm, D; Daifotis, A
      The clinical tolerability profile of alendronate

      INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
    31. McClung, M
      Results of special studies with alendronate

      INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
    32. Beauchesne, MF; Miller, PF
      Etidronate and alendronate in the treatment of postmenopausal osteoporosis

      ANNALS OF PHARMACOTHERAPY
    33. Pols, HAP; Felsenberg, D; Hanley, DA; Stepan, J; Munoz-Torres, M; Wilkin, TJ; Qin-sheng, G; Galich, AM; Vandormael, K; Yates, AJ; Stych, B
      Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study

      OSTEOPOROSIS INTERNATIONAL
    34. Bouxsein, ML; Parker, RA; Greenspan, SL
      Forearm bone mineral densitometry cannot be used to monitor response to alendronate therapy in postmenopausal women

      OSTEOPOROSIS INTERNATIONAL
    35. Machado, ABD; Hannon, R; Eastell, R
      Monitoring alendronate therapy for osteoporosis

      JOURNAL OF BONE AND MINERAL RESEARCH
    36. Monier-Faugere, MC; Geng, ZP; Paschalis, EP; Qi, QL; Arnala, I; Bauss, F; Boskey, AL; Malluche, HH
      Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: Effects on bone morphometry and mineral properties

      JOURNAL OF BONE AND MINERAL RESEARCH
    37. Porras, AG; Holland, SD; Gertz, BJ
      Pharmacokinetics of alendronate

      CLINICAL PHARMACOKINETICS
    38. Gonnelli, S; Cepollaro, C; Pondrelli, C; Martini, S; Montagnani, A; Monaco, R; Gennari, C
      Bone turnover and the response to alendronate treatment in postmenopausal osteoporosis

      CALCIFIED TISSUE INTERNATIONAL
    39. Downs, RW; Bone, HG; McIlwain, H; Baker, MZ; Yates, AJ; Lombardi, A; Krupa, D; Harning, R
      An open-label extension study of alendronate treatment in elderly women with osteoporosis

      CALCIFIED TISSUE INTERNATIONAL
    40. Brown, DL; Robbins, R
      Developments in the therapeutic applications of bisphosphonates

      JOURNAL OF CLINICAL PHARMACOLOGY
    41. Cocquyt, V; Kline, WF; Gertz, BJ; Van Belle, SJP; Holland, SD; DeSmet, M; Quan, H; Vyas, KP; Zhang, KYE; De Greve, J; Porras, AG
      Pharmacokinetics of intravenous alendronate

      JOURNAL OF CLINICAL PHARMACOLOGY
    42. Hamdy, RC
      Alendronate

      SOUTHERN MEDICAL JOURNAL
    43. Lindsay, R; Cosman, F; Lobo, RA; Walsh, BW; Harris, ST; Reagan, JE; Liss, CL; Melton, ME; Byrnes, CA
      Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: A randomized, controlled clinical trial

      JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM
    44. Raue, F
      Bisphosphonates - A new treatment principle in calcium and bone metabolismdisorders

      INTERNIST
    45. Ravn, P; Bidstrup, M; Wasnich, RD; Davis, JW; McClung, MR; Balske, A; Coupland, C; Sahota, O; Kaur, A; Daley, M; Cizza, G
      Alendronate and estrogen-progestin in the long-term prevention of bone loss: Four-year results from the early postmenopausal intervention cohort study - A randomized, controlled trial

      ANNALS OF INTERNAL MEDICINE
    46. GIULIANI N; PEDRAZZONI M; NEGRI G; PASSERI G; IMPICCIATORE M; GIRASOLE G
      BISPHOSPHONATES STIMULATE FORMATION OF OSTEOBLAST PRECURSORS AND MINERALIZED NODULES IN MURINE AND HUMAN BONE-MARROW CULTURES IN-VITRO AND PROMOTE EARLY OSTEOBLASTOGENESIS IN YOUNG AND AGED MICE IN-VIVO

      Bone
    47. RAVN P; CHRISTENSEN JO; BAUMANN C; CLEMMESEN B
      CHANGES IN BIOCHEMICAL MARKERS AND BONE MASS AFTER WITHDRAWAL OF IBANDRONATE TREATMENT - PREDICTION OF BONE MASS CHANGES DURING TREATMENT

      Bone
    48. GARCIAMORENO C; SERRANO S; NACHER M; FARRE M; DIEZ A; MARINOSO ML; CARBONELL J; MELLIBOVSKY L; NOGUES X; BALLESTER J; AUBIA J
      EFFECT OF ALENDRONATE ON CULTURED NORMAL HUMAN OSTEOBLASTS

      Bone
    49. FREDIANI B; ALLEGRI A; BISOGNO S; MARCOLONGO R
      EFFECTS OF COMBINED TREATMENT WITH CALCITRIOL PLUS ALENDRONATE ON BONE MASS AND BONE TURNOVER IN POSTMENOPAUSAL OSTEOPOROSIS 2 YEARS OF CONTINUOUS TREATMENT

      Clinical drug investigation
    50. ROSNER AJ; GRIMA DT; TORRANCE GW; BRADLEY C; ADACHI JD; SEBALDT RJ; WILLISON DJ
      COST-EFFECTIVENESS OF MULTI-THERAPY TREATMENT STRATEGIES IN THE PREVENTION OF VERTEBRAL FRACTURES IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS

      PharmacoEconomics
    51. ETTINGER B; PRESSMAN A; SCHEIN J
      CLINIC VISITS AND HOSPITAL ADMISSIONS FOR CARE OF ACID-RELATED UPPER GASTROINTESTINAL DISORDERS IN WOMEN USING ALENDRONATE FOR OSTEOPOROSIS

      American journal of managed care
    52. ASHWORTH LE
      FOCUS ON RALOXIFENE - A SELECTIVE ESTROGEN-RECEPTOR MODULATOR FOR PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

      Formulary
    53. SHIRAKI M; KUSHIDA K; FUKUNAGA M; KISHIMOTO H; KANEDA K; MINAGUCHI H; INOUE T; TOMITA A; NAGATA Y; NAKASHIMA M; ORIMO H
      A PLACEBO-CONTROLLED, SINGLE-BLIND STUDY TO DETERMINE THE APPROPRIATEALENDRONATE DOSAGE IN POSTMENOPAUSAL JAPANESE PATIENTS WITH OSTEOPOROSIS

      Endocrine journal
    54. TONINO RP
      ULTRASOUND AND ALENDRONATE - NEW TOOLS FOR OSTEOPOROSIS SCREENING ANDTREATMENT

      Cleveland Clinic journal of medicine
    55. AVIOLI LV
      THE ROLE OF CALCITONIN IN THE PREVENTION OF OSTEOPOROSIS

      Endocrinology and metabolism clinics of North America
    56. WATTS NB
      TREATMENT OF OSTEOPOROSIS WITH BISPHOSPHONATES

      Endocrinology and metabolism clinics of North America
    57. GREENSPAN SL; PARKER RA; FERGUSON L; ROSEN HN; MAITLANDRAMSEY L; KARPF DB
      EARLY CHANGES IN BIOCHEMICAL MARKERS OF BONE TURNOVER PREDICT THE LONG-TERM RESPONSE TO ALENDRONATE THERAPY IN REPRESENTATIVE ELDERLY WOMEN- A RANDOMIZED CLINICAL-TRIAL

      Journal of bone and mineral research
    58. SANDERS JL; TARJAN G; FOSTER SA; STERN PH
      ALENDRONATE INTERLEUKIN-1-BETA COTREATMENT INCREASES INTERLEUKIN-6 INBONE AND UMR-106 CELLS - DOSE DEPENDENCE AND RELATIONSHIP TO THE ANTIRESORPTIVE EFFECT OF ALENDRONATE/

      Journal of bone and mineral research
    59. BREUIL V; COSMAN F; STEIN L; HORBERT W; NIEVES J; SHEN V; LINDSAY R; DEMPSTER DW
      HUMAN OSTEOCLAST FORMATION AND ACTIVITY IN-VITRO - EFFECTS OF ALENDRONATE

      Journal of bone and mineral research
    60. GENNARI C; REGINSTER JY
      BISPHOSPHONATES AND OSTEOPOROSIS TREATMENT IN ITALY

      Aging
    61. LOURWOOD DL
      THE PHARMACOLOGY AND THERAPEUTIC UTILITY OF BISPHOSPHONATES

      Pharmacotherapy
    62. PIETSCHMANN P; STOHLAWETZ P; BROSCH S; STEINER G; SMOLEN JS; PETERLIK M
      THE EFFECT OF ALENDRONATE ON CYTOKINE PRODUCTION, ADHESION MOLECULE EXPRESSION, AND TRANSENDOTHELIAL MIGRATION OF HUMAN PERIPHERAL-BLOOD MONONUCLEAR-CELLS

      Calcified tissue international
    63. RINGE JD
      THE INTERPRETATION OF PRECLINICAL DATA IN PREDICTING BISPHOSPHONATE RESPONSE IN THE TREATMENT OF OSTEOPOROSIS

      Clinical therapeutics
    64. DEVOGELAER JP
      A RISK-BENEFIT ASSESSMENT OF ALENDRONATE IN THE TREATMENT OF INVOLUTIONAL OSTEOPOROSIS

      Drug safety
    65. HOSKING D; CHILVERS CED; CHRISTIANSEN C; RAVN P; WASNICH R; ROSS P; MCCLUNG M; BALSKE A; THOMPSON D; DALEY M; YATES AJ
      PREVENTION OF BONE LOSS WITH ALENDRONATE IN POSTMENOPAUSAL WOMEN UNDER 60 YEARS OF AGE

      The New England journal of medicine
    66. SARLI M; FRADINGER E; MORILLO S; REY P; ZANCHETTA J
      TREATMENT OF POST MENOPAUSAL OSTEOPOROSIS WITH INTRAVENOUS PAMIDRONATE IN PATIENTS WITH ESOPHAGOGASTRIC PATHOLOGY

      Medicina
    67. AZUMA Y; OUE Y; KANATANI H; OHTA T; KIYOKI M; KOMORIYA K
      EFFECTS OF CONTINUOUS ALENDRONATE TREATMENT ON BONE MASS AND MECHANICAL-PROPERTIES IN OVARIECTOMIZED RATS - COMPARISON WITH PAMIDRONATE ANDETIDRONATE IN GROWING RATS

      The Journal of pharmacology and experimental therapeutics
    68. FLOREANI A; TIZIAN L; LUISETTO G; BUDA A; MEGA A; NACCARATO R
      EFFECTS OF ALENDRONATE SODIUM ON SEVERE OSTEODYSTROPHY IN POSTMENOPAUSAL PATIENTS WITH PRIMARY BILIARY-CIRRHOSIS - A PILOT-STUDY

      Current therapeutic research
    69. LANZA F; RACK MF; SIMON TJ; LOMBARDI A; REYES R; SURYAWANSHI S
      EFFECTS OF ALENDRONATE ON GASTRIC AND DUODENAL MUCOSA

      The American journal of gastroenterology
    70. Yue, QY; Mortimer, O
      Alendronate - Risk for esophageal stricture

      JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
    71. SASS DA; BOWMAN AR; YUAN Z; MA Y; JEE WSS; EPSTEIN S
      ALENDRONATE PREVENTS CYCLOSPORINE-A-INDUCED OSTEOPENIA IN THE RAT

      Bone
    72. DEMERS LM
      THE MENOPAUSAL CONUNDRUM - OSTEOPOROSIS AND BREAST-CANCER

      Journal of clinical ligand assay
    73. CLEMMESEN B; RAVN P; ZEGELS B; TAQUET AN; CHRISTIANSEN C; REGINSTER JY
      A 2-YEAR PHASE-II STUDY WITH 1-YEAR OF FOLLOW-UP OF RISEDRONATE (NE-58095) IN POSTMENOPAUSAL OSTEOPOROSIS

      Osteoporosis international
    74. LENCHIK L; SARTORIS DJ
      CURRENT CONCEPTS IN OSTEOPOROSIS

      American journal of roentgenology
    75. EASTELL R; BLUMSOHN A
      THE VALUE OF BIOCHEMICAL MARKERS OF BONE TURNOVER IN OSTEOPOROSIS

      Journal of rheumatology
    76. RICO H
      PERSPECTIVES FOR THE TREATMENT OF OSTEOPOROSIS

      Calcified tissue international
    77. KARPF DB; SHAPIRO DR; SEEMAN E; ENSRUD KE; JOHNSTON CC; ADAMI S; HARRIS ST; SANTORA AC; HIRSCH LJ; OPPENHEIMER L; THOMPSON D
      PREVENTION OF NONVERTEBRAL FRACTURES BY ALENDRONATE - A METAANALYSIS

      JAMA, the journal of the American Medical Association
    78. REGINSTER JYL; HALKIN V; GOSSET C; DEROISY R
      THE ROLE OF BISPHOSPHONATES IN THE TREATMENT OF OSTEOPOROSIS

      Medicamentos de actualidad
    79. CHAVASSIEUX PM; ARLOT ME; REDA C; WEI L; YATES AJ; MEUNIER PJ
      HISTOMORPHOMETRIC ASSESSMENT OF THE LONG-TERM EFFECTS OF ALENDRONATE ON BONE QUALITY AND REMODELING IN PATIENTS WITH OSTEOPOROSIS

      The Journal of clinical investigation
    80. BONE HG; DOWNS RW; TUCCI JR; HARRIS ST; WEINSTEIN RS; LICATA AA; MCCLUNG MR; KIMMEL DB; GERTZ BJ; HALE E; POLVINO WJ
      DOSE-RESPONSE RELATIONSHIPS FOR ALENDRONATE TREATMENT IN OSTEOPOROTICELDERLY WOMEN

      The Journal of clinical endocrinology and metabolism
    81. JEAL W; BARRADELL LB; MCTAVISH D
      ALENDRONATE - A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC EFFICACY IN POSTMENOPAUSAL OSTEOPOROSIS

      Drugs
    82. CHRISTENSON RH
      BIOCHEMICAL MARKERS OF BONE METABOLISM - AN OVERVIEW

      Clinical biochemistry
    83. ADAMI S; FOSSALUZZA V; GATTI D; FRACASSI E; BRAGA V
      BISPHOSPHONATE THERAPY OF REFLEX SYMPATHETIC DYSTROPHY SYNDROME

      Annals of the Rheumatic Diseases
    84. LICATA AA
      BISPHOSPHONATE THERAPY

      The American journal of the medical sciences
    85. STOCK JL; BELL NH; CHESNUT CH; ENSRUD KE; GENANT HK; HARRIS ST; MCCLUNG MR; SINGER FR; YOOD RA; PRYORTILLOTSON S; WEI L; SANTORA AC
      INCREMENTS IN BONE-MINERAL DENSITY OF THE LUMBAR SPINE AND HIP AND SUPPRESSION OF BONE TURNOVER ARE MAINTAINED AFTER DISCONTINUATION OF ALENDRONATE IN POSTMENOPAUSAL WOMEN

      The American journal of medicine
    86. COLINA RE; SMITH M; KIKENDALL JW; WONG RKH
      A NEW PROBABLE INCREASING CAUSE OF ESOPHAGEAL ULCERATION - ALENDRONATE

      The American journal of gastroenterology
    87. RYAN SD; FRIED LP
      THE IMPACT OF KYPHOSIS ON DAILY FUNCTIONING

      Journal of the American Geriatrics Society
    88. REGINSTER JY
      NEW BISPHOSPHONATES FOR THE TREATMENT OF OSTEOPOROSIS - CONCERNS AND HOPES

      Revue du rhumatisme
    89. SELBY P
      ALENDRONATE TREATMENT FOR OSTEOPOROSIS - A REVIEW OF THE CLINICAL-EVIDENCE

      Osteoporosis international
    90. DEGROEN PC; LUBBE DF; HIRSCH LJ; DAIFOTIS A; STEPHENSON W; FREEDHOLM D; PRYORTILLOTSON S; SELEZNICK MJ; PINKAS H; WANG KK
      ESOPHAGITIS ASSOCIATED WITH THE USE OF ALENDRONATE

      The New England journal of medicine
    91. KIRK JK; SPANGLER JG
      ALENDRONATE - A BISPHOSPHONATE FOR TREATMENT OF OSTEOPOROSIS

      American family physician


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/01/21 alle ore 09:45:33